Table of Contents
ISRN Pharmacology
Volume 2014 (2014), Article ID 762127, 9 pages
http://dx.doi.org/10.1155/2014/762127
Clinical Study

Efficacy and Clinical Determinants of Antipsychotic Polypharmacy in Psychotic Patients Experiencing an Acute Relapse and Admitted to Hospital Stay: Results from a Cross-Sectional and a Subsequent Longitudinal Pilot Study

1Department of Neuroscience, Reproductive Sciences and Odontostomatology, University “Federico II” of Naples, Via Pansini 5, 80131 Naples, Italy
2Hermanas Hospitalarias, Villa San Giuseppe Hospital, 63100 Ascoli Piceno, Italy
3NHS, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “G. Mazzini”, ASL 4, 64100 Teramo, Italy
4Department of Neurosciences and Imaging, University “G. d’Annunzio” of Chieti, 66013 Chieti, Italy
5Department of Life, Health and Environmental Sciences, University of L’Aquila, 67010 L’Aquila, Italy
6FORIPSI, 00199 Rome, Italy

Received 22 September 2013; Accepted 30 October 2013; Published 27 January 2014

Academic Editors: G. Froldi, J.-A. Mico, and K. Wada

Copyright © 2014 Felice Iasevoli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. F. Lehman, J. A. Lieberman, L. B. Dixon et al., “Practice guideline for the treatment of patients with schizophrenia, second edition,” American Journal of Psychiatry, vol. 161, supplement 2, pp. 1–56, 2004. View at Google Scholar
  2. A. L. Miller, M. L. Crismon, A. J. Rush et al., “The Texas medication algorithm project: clinical results for schizophrenia,” Schizophrenia Bulletin, vol. 30, no. 3, pp. 627–647, 2004. View at Google Scholar
  3. C. Tsutsumi, H. Uchida, T. Suzuki et al., “The evolution of antipsychotic switch and polypharmacy in natural practice—a longitudinal perspective,” Schizophrenia Research, vol. 130, no. 1–3, pp. 40–46, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Santone, C. Bellantuono, P. Rucci, A. Picardi, A. Preti, and G. de Girolamo, “Patient characteristics and process factors associated with antipsychotic polypharmacy in a nationwide sample of psychiatric inpatients in Italy,” Pharmacoepidemiology and Drug Safety, vol. 20, no. 5, pp. 441–449, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. T. Xiang, F. Dickerson, J. Kreyenbuhl et al., “Common use of anticholinergic medications in older patients with schizophrenia: findings of the Research on Asian Psychotropic Prescription Pattern (REAP) study, 2001–2009,” International Journal of Geriatric Psychiatry, vol. 28, no. 3, pp. 305–311, 2013. View at Google Scholar
  6. Y.-T. Xiang, Y.-Z. Weng, C.-M. Leung, W.-K. Tang, and G. S. Ungvari, “Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia,” Pharmacopsychiatry, vol. 40, no. 2, pp. 47–52, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. R. M. Procyshyn, W. G. Honer, T. K. Y. Wu et al., “Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients,” Journal of Clinical Psychiatry, vol. 71, no. 5, pp. 566–573, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. J. A. Gallego, J. Nielsen, M. De Hert, J. M. Kane, and C. U. Correll, “Safety and tolerability of antipsychotic polypharmacy,” Expert Opin Drug Saf, vol. 11, no. 4, pp. 527–542, 2012. View at Google Scholar
  9. N. K. Aggarwal, M. J. Sernyak, and R. A. Rosenheck, “Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications,” Journal of Clinical Psychopharmacology, vol. 32, no. 3, pp. 323–328, 2012. View at Google Scholar
  10. A. Waterreus, V. A. Morgan, D. Castle et al., “Medication for psychosis—consumption and consequences: the second Australian national survey of psychosis,” Australian & New Zealand Journal of Psychiatry, vol. 46, no. 8, pp. 762–773, 2012. View at Google Scholar
  11. W. W. Fleischhacker and H. Uchida, “Critical review of antipsychotic polypharmacy in the treatment of schizophrenia,” The International Journal of Neuropsychopharmacology, pp. 1–11, 2012. View at Google Scholar
  12. C. G. Taylor, S. W. Flynn, S. Altman, T. Ehmann, G. W. MacEwan, and W. G. Honer, “An open trial of risperidone augmentation of partial response to clozapine,” Schizophrenia Research, vol. 48, no. 1, pp. 155–158, 2001. View at Google Scholar · View at Scopus
  13. E. W. Waring, P. G. Devin, and V. Dewan, “Treatment of schizophrenia with antipsychotics in combination,” Canadian Journal of Psychiatry, vol. 44, no. 2, pp. 189–190, 1999. View at Google Scholar · View at Scopus
  14. V. Lerner, B. Chudakova, S. Kravets, and I. Polyakova, “Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report,” Clinical Neuropharmacology, vol. 23, no. 5, pp. 284–286, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. C. U. Correll, C. Rummel-Kluge, C. Corves, J. M. Kane, and S. Leucht, “Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials,” Schizophrenia Bulletin, vol. 35, no. 2, pp. 443–457, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. M. W. Lochmann van Bennekom, H. J. Gijsman, and F. G. Zitman, “Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness,” Journal of Psychopharmacology, vol. 27, no. 4, pp. 327–336, 2013. View at Google Scholar
  17. M. B. First, M. Gibbon, R. L. Spitzer et al., Structured Clinical Interview for DSM-IV Axis I Disorders/Patient Edition (SCID-I/P), American Psychiatric Press, Biometrics Research, New York State Psychiatric Institute, New York, NY, USA, 2002.
  18. M. B. First, M. Gibbon, R. L. Spitzer et al., Structured Clinical Interview for DSM-IV Axis II Personality Disorders, (SCID-II), American Psychiatric Press, Washington, DC, USA, 1997.
  19. J. M. Kane, G. Honigfeld, J. Singer, and H. Meltzer, “Clozapine in treatment-resistant schizophrenics,” Psychopharmacology Bulletin, vol. 24, no. 1, pp. 62–67, 1988. View at Google Scholar · View at Scopus
  20. D. M. Gardner, A. L. Murphy, H. O'Donnell, F. Centorrino, and R. J. Baldessarini, “International consensus study of antipsychotic dosing,” American Journal of Psychiatry, vol. 167, no. 6, pp. 686–693, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. R. C. Young, J. T. Biggs, V. E. Ziegler, and D. A. Meyer, “A rating scale for mania: reliability, validity and sensitivity,” British Journal of Psychiatry, vol. 133, no. 11, pp. 429–435, 1978. View at Google Scholar · View at Scopus
  22. R. Roncone, J. Ventura, M. Impallomeni et al., “Reliability of an Italian standardized and expanded Brief Psychiatric Rating Scale (BPRS 4.0) in raters with high vs. low clinical experience,” Acta Psychiatrica Scandinavica, vol. 100, no. 3, pp. 229–236, 1999. View at Google Scholar · View at Scopus
  23. M. Hamilton, “Development of a rating scale for primary depressive illness,” The British Journal of Social and Clinical Psychology, vol. 6, no. 4, pp. 278–296, 1967. View at Google Scholar · View at Scopus
  24. M. Hamilton, “The assessment of anxiety states by rating,” The British Journal of Medical Psychology, vol. 32, no. 1, pp. 50–55, 1959. View at Google Scholar · View at Scopus
  25. W. Guy, Clinical Global Impression. ECDEU Assessment Manual for Psychopharmacology (Revised), National Institute of Mental Heatlh, Rockville, Md, USA, 1976.
  26. A. Fossati, A. Di Ceglie, E. Acquarini, and E. S. Barratt, “Psychometric properties of an Italian version of the Barrat Impulsiveness Scale-11 (BIS-11) in nonclinical subjects,” Journal of Clinical Psychology, vol. 57, no. 6, pp. 815–828, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Bressi, G. Taylor, J. Parker et al., “Cross validation of the factor structure of the 20-item Toronto Alexithymia Scale: An Italian Multicenter Study,” Journal of Psychosomatic Research, vol. 41, no. 6, pp. 551–559, 1996. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Rossi, L. Arduini, S. De Cataldo, and P. Stratta, “Subjective response to neuroleptic medication: a validation study of the Italian version of the drug attitude inventory (DAI),” Epidemiologia e Psichiatria Sociale, vol. 10, no. 2, pp. 107–114, 2001. View at Google Scholar · View at Scopus
  29. A. Rossi, A. Bagalà, V. Del Curatolo, F. Scapati, M. M. Bernareggi, and M. G. Giustra, “Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder,” Human Psychopharmacology, vol. 24, no. 7, pp. 574–583, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. J. C. Huffman, T. E. Chang, L. E. Durham, and A. P. Weiss, “Antipsychotic polytherapy on an inpatient psychiatric unit: How does clinical practice coincide with Joint Commission guidelines?” General Hospital Psychiatry, vol. 33, no. 5, pp. 501–508, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. B. L. Handen and R. Gilchrist, “Practitioner review: psychopharmacology in children and adolescents with mental retardation,” Journal of Child Psychology and Psychiatry and Allied Disciplines, vol. 47, no. 9, pp. 871–882, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Kirkpatrick and S. Galderisi, “Deficit schizophrenia: an update,” World Psychiatry, vol. 7, no. 3, pp. 143–147, 2008. View at Google Scholar · View at Scopus
  33. J. T. Suokas, J. M. Suvisaari, J. Haukka et al., “Description of long-term polypharmacy among schizophrenia outpatients,” Social Psychiatry and Psychiatric Epidemiology, vol. 48, no. 4, pp. 631–638, 2013. View at Google Scholar
  34. G. Chouinard, “Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteris for the disorder and its treatment,” Schizophrenia Research, vol. 5, no. 1, pp. 21–33, 1991. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Porcelli, B. Balzarro, and A. Serretti, “Clozapine resistance: augmentation strategies,” European Neuropsychopharmacology, vol. 22, no. 3, pp. 165–182, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. O. Agid, P. Seeman, and S. Kapur, “The “delayed onset” of antipsychotic action—an idea whose time has come and gone,” Journal of Psychiatry and Neuroscience, vol. 31, no. 2, pp. 93–100, 2006. View at Google Scholar · View at Scopus